We have located links that may give you full text access.
Citrus Tangeretin Improves Skeletal Muscle Mitochondrial Biogenesis via Activating the AMPK-PGC1-α Pathway In Vitro and In Vivo: A Possible Mechanism for Its Beneficial Effect on Physical Performance.
Journal of Agricultural and Food Chemistry 2018 November 15
Mitochondrial biogenesis is a key factor, which influences the function of skeletal muscle. Increasingly, flavonoids are reported to have the potential ability of regulating mitochondrial biogenesis. In this study, we investigated the effects of tangeretin, a polymethoxylated flavonoid isolated from mandarin fruits, on mitochondrial biogenesis and its underlying mechanisms. The tangeretin was obtained from the peel of "Dahongpao" tangerine by macroporous adsorptive resins combined with preparative-high performance liquid chromatography. The activity of mitochondrial biogenesis was explored by using mouse-derived C2C12 myoblasts and Kunming mice. Results showed that the purity of tangeretin obtained was 98.64%, and it could effectively activate mitochondrial biogenesis signaling pathway both at gene and at protein levels in C2C12 myoblasts. Animal experiments showed that tangeretin pretreatment could markedly improve exercise performance (the time of hanging wire and run to fatigue was obviously increased 1.6-fold and 2.1-fold in the high-dose tangeretin group, respectively), and the transmission electron microscopy, Western blotting, and immunohistochemistry further indicated that tangeretin increased mitochondria number and activated mitochondrial biogenesis signaling axis. Our findings suggest that tangeretin enhanced mitochondrial biogenesis via activating the AMPK-PGC1-α pathway, resulting in the improvement of exercise performance, and tangeretin may be a potentially novel mitochondria regulator in foods.
Full text links
Trending Papers
A Personalized Approach to the Management of Congestion in Acute Heart Failure.Heart International 2023
Potential Mechanisms of the Protective Effects of the Cardiometabolic Drugs Type-2 Sodium-Glucose Transporter Inhibitors and Glucagon-like Peptide-1 Receptor Agonists in Heart Failure.International Journal of Molecular Sciences 2024 Februrary 21
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app